To evaluate whether markers of the acute-phase response in patients presenting with arthralgia and positive anticitrullinated protein antibodies (ACPA) and/or immunoglobulin M rheumatoid factor (IgM-RF) could be predictive for the development of arthritis.
measured in baseline serum samples. Gene expression focusing on a predefined panel of genes coding for inflammatory molecules was measured by multiplex ligationdependent probe amplification.
Results
Thirty-five patients (26%) developed arthritis within a median time of 11 months (interquartile range 3.7−18 mo). Circulating levels of cytokines, SPLA2, hsCRP, and PCT were not different between patients with progression to clinical arthritis and those without progression. However, a trend for IL-12p70, TNF-α, IL-10, IL-6, and SPLA2 was observed. No correlation between messenger RNA (mRNA) expression levels of inflammatory genes and progression to arthritis was found. Subgroup analysis of patients with early progression to arthritis showed higher levels of mRNA expression of poly(A)-specific ribonuclease and polycomb complex protein BMI-1 compared to patients without progression to arthritis.
Conclusion
Although low-grade inflammation is present before onset of clinical arthritis in large cohorts and can be detected using consecutive measurements, a single measurement of acute-phase reactants seems to have limited value for prediction of development of arthritis in individual patients.
INTRODUCTION
Rheumatoid arthritis (RA) is a chronic, systemic inflammatory disease, of which the exact etiology remains to be elucidated. In clinically active RA, inflammation is represented in the blood by elevated levels of acute-phase reactants such as highsensitivity C-reactive protein (hsCRP), which can be used as a diagnostic marker for disease activity.
About half of patients with RA have specific serologic abnormalities several years before the onset of symptoms. The presence of elevated serum level of immunoglobulin M rheumatoid factor (IgM-RF) or anticitrullinated protein antibodies (ACPA) in a healthy individual implies an increased risk for development of RA. 1 Further, a rise in CRP and secretory phospholipase A2 (SPLA2) levels has been associated with the development of RA. 2 Also, several cytokines, cytokinerelated factors, and chemokines are elevated prior to diagnosis of RA. 3 However, it remains unclear whether these serological markers can be used to predict the development of arthritis prior to disease onset. Our study was conducted to test the hypothesis that acute-phase proteins can be used as markers to predict the development of RA in patients at increased risk.
MATERIALS AND METHODS

Study population
The study population has been described in previous publications. 
Statistical analysis
Baseline demographic and clinical variables are tabulated and descriptive statistics are presented as numbers (%), medians with interquartile ranges (IQR), or means with SD when a normal distribution could be assumed.
Differences in marker levels between groups were determined with an unpaired T test. Correlations were determined by logistic regression analysis. CBA, MLPA, and 8 biomarker levels were transformed with their natural logarithm prior to statistical analysis to normalize the data.
Subgroup analysis comparing early progressors (defined as patients with development of arthritis within the first IQR after inclusion in the study) with nonprogressors was performed for all markers. Smoking was taken into account as a possible confounder. A 2-tailed p value < 0.05 was considered to indicate statistical significance.
RESULTS
Patient characteristics
A total of 137 ACPA-and/or IgMRF-positive arthralgia patients were included; patient characteristics are shown in 
Circulating levels of cytokines
Circulating levels of cytokines were not different between patients with progression to clinical arthritis and those without progression. However, a trend for increased levels of IL-12p70, TNF-α, IL-10, and IL-6 could be observed, with higher levels in patients who progressed to arthritis (p = 0.07, p = 0.07, p = 0.10, and p = 0.05, respectively). Subgroup analysis of circulating levels of cytokines in early progressors as compared to patients without progression to arthritis showed no significant difference ( Table 2 ). Subgroup analysis comparing smokers and nonsmokers showed comparable results: levels of ACPA and RF titers were not independently associated with levels of circulating cytokines (data not shown).
Messenger RNA (mRNA) biomarkers.
No significant correlation could be observed between progression to arthritis and mRNA expression of the following inflammatory genes ( Table 2) 
Biomarker levels
Mean SPLA2, hsCRP, and PCT levels were not different between patients who developed arthritis and those who did not; a trend toward higher SPLA2 levels in patients with arthritis was observed (p = 0.07; 
DISCUSSION
Our study of patients with an increased risk of developing RA was conducted to investigate whether differences in inflammatory patterns in those patients who developed arthritis could be observed before clinical signs of arthritis could be confirmed. We found no evidence of a more pronounced systemic acute-phase response, higher cytokine levels, or higher expression of proinflammatory gene markers in patients who later progressed to arthritis than in those who did not, although a number of the biomarkers showed a trend toward higher levels in those who later developed arthritis. These data indicate that any possible local inflammatory processes in the joints of patients with Seropositive arthralgia do not result in a discernible systemic acute-phase response activation.
These results are in contrast with our previous studies, in which we reported elevation of CRP and SPLA2 levels in preclinical RA. 2, 10 A possible explanation for this discrepancy could be the difference in study design. In these previous studies, multiple, longitudinally collected serum samples were analyzed, and a slight but significant rise in CRP and SPLA2 levels was observed before RA onset, in contrast to stable levels in healthy controls. However, CRP and SPLA2 levels in preclinical RA were still within the normal range and therefore large numbers of samples are needed to detect such small changes. In our study a trend was observed toward higher levels of IL-12p70, TNF-α, IL-10, IL-6, PARN, lymphotoxin α (LTA), BMI-1, and SPLA2 in arthritis progressors; higher levels of PARN and BMI-1 were observed in early progressors. More significant differences might be observed when larger numbers of samples are analyzed. Also in our study, hsCRP levels of patients with arthralgia were higher than hsCRP levels of healthy controls, indicating that patients with arthralgia have a slightly activated acute-phase response on the group level.
Thus, although evidence exists for an induction of inflammation prior to the onset of RA, our data indicate that acute-phase response markers such as CRP and SPLA2
are not useful in clinical practice as predictors of development of arthritis in individual high-risk patients. This is in accord with results from other studies in which hsCRP and SPLA2 in a single pre-RA serum sample were not increased in
